Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges
Reported by CNBC · cnbc.com · August 4, 2026
Merck cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharmaceuticals.
What the tape says
What to watch: Merck & Co. Inc. (MRK) cut guidance — a cut like this often precedes further estimate revisions across the sector.
Market reaction today: $MRK -1.24%
Tone and severity are deterministic keyword classification — not a prediction, a member vote, or a recommendation. Figures are extracted from the headline as published. Wook does not republish CNBC's reporting.
Your read
Discussion
No one has weighed in yet. Start the discussion on this story.
Headline and link are attributed to CNBC. Wook of Wall Street is an independent research tool and is not affiliated with CNBC. Nothing here is financial advice or a recommendation — research and educational content only.